Creative Touch Permanent Makeup and Aesthetics

Gamma-linolenic acid is an omega-6 fatty acid that sits downstream of linoleic acid in the metabolic pathway but behaves quite differently; its primary outputs are anti-inflammatory rather than pro-inflammatory. GLA is rapidly elongated to dihomo-gamma-linolenic acid (DGLA), which generates prostaglandin E1 and 15-HETrE, both of which suppress the inflammatory mediators driving conditions like atopic dermatitis. The reason GLA supplementation is clinically relevant – particularly in atopic presentations – is that the enzyme converting linoleic acid to GLA is often impaired, creating a functional deficit even when LA intake is adequate. Evidence from individual trials supports GLA supplementation in atopic presentations, particularly when combined with EPA; a Cochrane review of oral essential fatty acid supplementation for eczema rated the overall evidence as sparse and of uncertain quality, reflecting the limitations of the trial pool rather than contradicting individual positive findings.

Gamma-linolenic acid (GLA) is an 18-carbon omega-6 polyunsaturated fatty acid (PUFA) with three double bonds, produced in the body when linoleic acid (LA) is acted on by the enzyme delta-6 desaturase. It is found preformed in evening primrose oil, borage oil, and hemp seed oil – sources that allow GLA to be supplemented directly without relying on that enzymatic conversion step. Its position within the omega-6 family is worth stating clearly at the outset: GLA does not follow the pro-inflammatory pathway that gives omega-6 its reputation. Its primary metabolic outputs run in the opposite direction. ^[2]

The Anti-Inflammatory Pathway

Once absorbed, GLA is rapidly elongated to dihomo-gamma-linolenic acid (DGLA) by the elongase enzyme ELOVL5. DGLA sits at a metabolic crossroads: it can be converted to arachidonic acid (AA) by delta-5 desaturase, entering the pro-inflammatory pathway, or it can be acted on by COX-1 to generate prostaglandin E1 (PGE1) and by 15-lipoxygenase to generate 15-HETrE. Both PGE1 and 15-HETrE are anti-inflammatory mediators. Critically, 15-HETrE directly inhibits 5-lipoxygenase, blocking the conversion of AA to leukotriene B4 (LTB4) – one of the primary drivers of the inflammatory cascade in atopic dermatitis. GLA supplementation therefore generates anti-inflammatory effects through an entirely omega-6 pathway, without requiring omega-3 at all. ^[1]

The Delta-6 Desaturase Bottleneck

The reason GLA warrants specific attention – rather than simply advising adequate LA intake – is that the delta-6 desaturase conversion step is frequently impaired. In atopic dermatitis, this enzymatic activity is reduced, meaning affected individuals cannot efficiently convert dietary LA to GLA regardless of how much LA they consume. The downstream consequence is a reduced DGLA pool, less PGE1 and 15-HETrE production, and a shift in the omega-6 balance toward the pro-inflammatory AA branch. Supplementing GLA directly bypasses this bottleneck entirely, delivering substrate to the DGLA pathway without depending on an enzymatic step that is not functioning normally. ^[2]

This makes GLA meaningfully different from simply increasing LA intake in atopic presentations. More LA does not help if the conversion enzyme is the limiting factor.

Evidence and Its Limits

Individual clinical trials support GLA supplementation in inflammatory skin conditions. A study of 130 participants with mild atopic dermatitis given GLA-rich oil showed reduced TEWL and improved stratum corneum integrity at four weeks compared to control. Combined GLA and omega-3 EPA has the strongest combined evidence for inflammatory skin presentations: GLA suppresses LTB4 through 15-HETrE inhibition whilst EPA displaces AA from membrane phospholipids – two mechanistically distinct routes toward the same outcome. ^[1]

The honest calibration note: the Cochrane review of oral essential fatty acid supplementation for established atopic eczema concluded that the evidence was sparse and of uncertain quality, stopping short of a confident recommendation. cochrane.org Individual positive trials and the Cochrane conclusion coexist; neither negates the other, and both are worth knowing.